We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,914.00
Bid: 1,912.00
Ask: 1,915.00
Change: -10.00 (-0.52%)
Spread: 3.00 (0.157%)
Open: 1,902.00
High: 1,916.00
Low: 1,902.00
Prev. Close: 1,924.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Broker tips: Johnston Press, Direct Line, Hikma Pharmaceuticals

Thu, 04th Aug 2016 11:01

(ShareCast News) - Johnston Press shares plunged on Thursday as Numis placed its rating and target price 'under review' after the company swung to a first half loss.For the 26 weeks to 2 July, the company posted a statutory pre-tax loss of £183.7m versus a £2.2m profit the year before, as it booked a £183.6m non-cash impairment reflecting a change of assumptions on its publishing titles and print assets.Advertising revenues were down 17.9% in the first quarter but improved marginally, with a 15% drop in the second quarter despite the impact of the run-up to and uncertainty following the UK's vote to leave the European Union in June.Chief executive Ashley Highfield said the market continues to be challenging and uncertainty surrounding the outcome of the Brexit negotiations has caused further softness in some segments of the advertising market, in June and July.Numis said the half year results came in below its estimates at every level."Our key issue at Johnston remains debt which has risen to £209m (from £179.4m) representing almost 4x our annualised EBITDA."This material debt pile, relative to cashflows, in combination with the declining and uncertain trading environment place a significant question mark on the equity value in the business."Numis said it expects to cut estimates "reasonably sharply" in both fiscal years 2016 and 2017. Direct Line Insurance Group's rating has been downgraded to 'hold' from 'buy' by Berenberg as the broker said "questions remain about earnings sustainability"."We believe there is some risk regarding the sustainability of Direct Line's earnings," Berenberg said in a note on Wednesday."High reserve releases, lower than forecast cost savings and a shrinking direct market all cast doubt on future earnings."Berenberg said older accident years have been incredibly profitable for Direct Line but these years are now contributing increasingly less releases.The broker said it does not expect to see the same developments in more recent accident years. Berenberg believes it will be difficult for management to offset falling reserve releases with the current accident year and operating improvements."As reserve releases decline, we expect earnings to be flat at best, thus we believe it will be challenging to grow the dividend from here," the broker said.Berenberg reiterated a target price of 406p.Direct Line on Tuesday posted its half year report for the six months to 30 June on Tuesday. Operating profit fell 5% to £316.9m, hurt by lower investment gains and the new Flood Re levy, but the group beat its own consensus estimates of £263m. Analysts at Citi downgraded their recommendation on shares of Hikma Pharmaceuticals in the wake of the company´s trading update which was issued after the close of trading in London on 3 August.Hikma flagged new drug approvals were arriving more slowly than expected and the phasing of litigation costs at US generics.On the basis of the above, the broker´s analysts lowered their recommendation on the shares from 'buy' to 'neutral' and set a target price of 2,600p.They also lowered estimates for the drugmaker´s core 2016 earnings before interest and taxes and earnings per share by 9.0% to $367m and $1.08, respectively - below the equivalent figures of $420m and $1.22 expected by the consensus.EPS estimates from 2017 onwards were cut by between 2% and 5% from 2017 onwards, with rates in foreign exchange markets expected to be an "incremental headwind".What was Citi´s view? "Developments at US Generics at best can be described as a 'short term hiccup'. At worse, sentiment concerns around the revenue/margin potential from the Roxane pipeline will increase, which is not helped by the lack of clarity on the pipeline given commercial sensitivities until 2017."If one were to cut his Roxane pipeline estimates by half, that would lead to EPS downgrades of between -15.0% and -20.0%, Citi said.Citi estimated the company´s net present value (NPV) at 2,900p, with a weighted average cost of capital of 8.0%, a terminal growth value (the rate at which free cash flows are expected to grow for eternity) of 2.0% and cable´s exchange rate at 1.32.
More News
13 May 2022 16:01

UK shareholder meetings calendar - next 7 days

Monday 16 May 
88 Energy LtdAGM
Allianz Technology Trust PLCAGM
Blackbird PLCAGM
BSF Enterprise PLCGM
Crossword Cybersecurity PLCAGM
DigitalBox PLCAGM
Ethernity Networks LtdAGM
Jubilee Metals Group PLCGM - re right of directors to allot equity securities for cash
Mast Energy Developments PLCAGM
Metal Tiger PLCAGM
Tuesday 17 May 
Accesso Technology Group PLCAGM
Capital & Regional PLCAGM
Chaarat Gold Holdings LtdAGM
Chesnara PLCAGM
Equals Group PLCAGM
European Assets Trust PLCAGM
Fidelity Japan Trust PLCAGM
Fintel PLCAGM
Fresnillo PLCAGM
GCP Asset Backed Income Fund LtdAGM
GENinCode PLCFull Year Results
Greggs PLCAGM
IQGeo Group PLCAGM
Kefi Gold & Copper PLCGM re share placing
Mears Group PLCAGM
Mercantile Investment Trust PLCAGM
Vitec Group PLCAGM
Vivo Energy PLCAGM
Wednesday 18 May  
ABCAM PLCAGM
abrdn PLCAGM in Edinburgh
Alliance Pharma PLCAGM
Burford Capital LtdAGM
Coats Group PLCAGM
CVC Credit Partners European Opportunities LtdAGM
EKF Diagnostics Holdings PLCAGM
Highcroft Investments PLCAGM
Impax Environmental Markets PLCAGM
JPMorgan American Investment Trust PLCAGM
Keller Group PLCAGM
LMS Capital PLCAGM
Merchants Trust PLCAGM
PensionBee Group PLCAGM
Permanent TSB Group Holdings PLCAGM
PYX Resources LtdAGM
Riverstone Credit Opportunities Income PLCAGM
Schroder UK Public Private Trust PLCAGM
Science Group PLCAGM
Seplat Energy PLCAGM
TI Fluid Systems PLCAGM
Vesuvius PLCAGM
Thursday 19 May  
Bigblu Broadband PLCAGM
Brand Architekts Group PLCGM re takeover of InnovaDerma
Capital & Regional PLCAGM
Computacenter PLCAGM
Cornish Metals IncGM re equity raise
Dialight PLCAGM
Ebiquity PLCAGM
Eqtec PLCAGM
Essentra PLCAGM
Fevertree Drinks PLCAGM
Gamma Communications PLCAGM
Genuit Group PLCAGM
Headlam Group PLCAGM
Inchcape PLCAGM
InnovaDerma PLCGM re takeover by Brand Architekts
Irish Residential Properties REIT PLCAGM
K3 Business Technology Group PLCAGM
Light Science Tech Holdings PLCAGM
Live Co Group PLCGM
McColl's Retail Group PLCAGM
musicMagpie PLCAGM
Network International Holdings PLCAGM
Next PLCAGM
Pharos Energy PLCAGM
Property Franchise Group PLCAGM
Rotala PLCAGM
Smart Metering Systems PLCAGM
St James's Place PLCAGM
Tyman PLCAGM
Friday 20 May  
Bank of Cyprus Holdings PLCAGM
Croda International PLCAGM
Deliveroo PLCAGM
Georgia Capital PLCAGM
Hikma Pharmaceuticals PLCEGM re capital reduction
Keywords Studios PLCAGM
Real Estate Investors PLCAGM
Reckitt Benckiser Group PLCAGM
Resolute Mining LtdAGM
Restore PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
6 May 2022 09:47

LONDON BROKER RATINGS: Downgrades for Centrica and Rathbones

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
5 May 2022 12:11

LONDON MARKET MIDDAY: Pound slips as BoE opts for quarter-point hike

(Alliance News) - Stock prices in London were higher, while the pound was flat, on Thursday, after the Bank of England as expected raised UK interest rates by a quarter percentage point.

Read more
5 May 2022 10:51

Signs of slowdown on the continent

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com

SIGNS OF SLOWDOWN ON THE CONTINENT (1051 GMT)

Read more
5 May 2022 09:24

TOP NEWS: Hikma shares fall 10% on delay to Jazz Pharmaceuticals drug

(Alliance News) - Shares in Hikma Pharmaceuticals PLC fell early Thursday, after the drugmaker downgraded guidance for its Generics business due to the delayed launch of a generic of the Xyrem treatment for narcolepsy.

Read more
5 May 2022 08:58

LONDON MARKET OPEN: Mondi and Shell lift FTSE 100 after strong updates

(Alliance News) - Stock prices in London opened sharply higher on Thursday after the US Federal reserve assuaged fears over further aggressive monetary policy tightening, while positive updates from Mondi and Shell boosted the FTSE 100.

Read more
5 May 2022 08:02

Hikma cuts 2022 generics guidance due to drug launch delay

(Sharecast News) - Hikma Pharmaceuticals cut guidance for its generics business on Thursday, citing a delay to a drug launch.

Read more
29 Apr 2022 17:44

IN BRIEF: Hikma says has not entered license agreement with Opiant

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Confirms that it has not entered into any transaction with Opiant Pharmaceutical UK, following a PR Newswire announcement issued on Friday. The release said Opiant and Hikma entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK.

Read more
29 Apr 2022 17:01

LONDON MARKET CLOSE: Stocks end volatile April on high note

(Alliance News) - Stocks in London on Friday ended a volatile month of April in a positive fashion, amid a continued rush of company earnings, while markets in the US sank as high-profile tech names disappointed.

Read more
29 Apr 2022 09:09

Hikma Pharmaceuticals notes "slow" start for Generics business in 2022

(Alliance News) - Hikma Pharmaceuticals PLC said on Friday that both its Injectables and Branded businesses have performed well at the start of the year but noted its Generics business has experienced some headwinds.

Read more
29 Apr 2022 08:32

Hikma shares fall as generics unit faces headwinds

(Sharecast News) - Hikma Pharmaceuticals shares fell as the company reported headwinds at its generics business.

Read more
29 Apr 2022 08:25

LONDON BRIEFING: Pearson has positive first quarter, buys language app

(Alliance News) - Educational materials publisher Pearson on Friday provided a positive update on first quarter trading, while also announcing a new acquisition.

Read more
21 Apr 2022 16:06

UK dividends calendar - next 7 days

Friday 22 April 
JPMorgan Global Emerging Markets Income Trust PLCdividend payment date
Henderson Eurotrust PLCdividend payment date
Monday 25 April 
abrdn Smaller Cos Income Trust PLCdividend payment date
Tuesday 26 April 
Anglo American PLCdividend payment date
Anglo American PLCspecial dividend payment date
Invesco Asia Trust PLCdividend payment date
Wednesday 27 April 
Close Brothers Group PLCdividend payment date
Thursday 28 April 
4imprint Group PLCex-dividend date
AEW UK REIT PLCex-dividend date
AVI Japan Opportunity Trust PLCex-dividend date
Bakkavor Group PLCex-dividend date
Carr's Group PLCex-dividend date
Coats Group PLCex-dividend date
CQS Natural Resources Growth & Income PLCex-dividend date
CQS New City High Yield Fund Ltdex-dividend date
Derwent London PLCex-dividend date
Drax Group PLCex-dividend date
Ecofin Global Utilities & Infrastructure Trust PLCex-dividend date
Fresnillo PLCex-dividend date
Henderson Far East Income Trust PLCex-dividend date
Hikma Pharmaceuticals PLCdividend payment date
HSBC Holdings PLCdividend payment date
Kenmare Resourcesex-dividend date
LSL Property Services PLCex-dividend date
M&G PLCdividend payment date
M P Evans Group PLCex-dividend date
Mobius Investment Trust PLCex-dividend date
Morgan Advanced Materials PLCex-dividend date
Morgan Sindall Group PLCex-dividend date
Mortgage Advice Bureau (Holdings) PLCex-dividend date
Northamber plcdividend payment date
Porvair PLCex-dividend date
Reckitt Benckiser Group PLCex-dividend date
Rightmove PLCex-dividend date
Sabre Insurance Group PLCex-dividend date
Sabre Insurance Group PLCspecial ex-dividend date
Schroder Oriental Income Fund Ltdex-dividend date
Secure Income REIT PLCex-dividend date
Smart Metering Systems PLCdividend payment date
St James's Place PLCex-dividend date
Synthomer PLCex-dividend date
Tate & Lyle PLCspecial ex-dividend date
TT Electronics PLCex-dividend date
Tyman PLCex-dividend date
XP Power Ltddividend payment date
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
21 Apr 2022 14:37

IN BRIEF: Hikma Pharmaceuticals completes Custopharm deal

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Completes acquisition of Custopharm Inc from Water Street Healthcare Partners, following approval from the US Federal Trade Commission. Back in September, Hikma agreed to buy the California-based generic injectable products company for a total of up to USD425 million. Deal will add up to 13 approved products and additional pipeline products.

Read more
20 Apr 2022 09:16

IN BRIEF: Hikma gets preliminary US approval for Custopharm acquisition

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Receives preliminary approval from the US Federal Trade Commission for its planned acquisition of Custopharm Inc. Back in September, Hikma agreed to buy the California, US-based generic injectable products company for a total of up to USD425 million.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.